Completed PHASE2 INTERVENTIONAL 4-arm NCT00080236

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)

Sponsor: Conatus Pharmaceuticals Inc.

Conditions Carcinoma, Hepatocellular Cholestasis Hepatitis Liver Transplantation

Interventions IDN-6556 Placebo

Updated 6 times since 2017 Last updated: Aug 8, 2012 Started: Nov 30, 2003 Primary completion: Jan 31, 2006 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Hepatocellular and Cholestasis, this trial is completed. The trial is conducted by Conatus Pharmaceuticals Inc. and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conatus Pharmaceuticals Inc.
Idun Pharmaceuticals

Data source: Conatus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Cincinnati, United States , Dallas, United States , Hanover, Germany , Indianapolis, United States , Los Angeles, United States , Mainz, Germany , New Orleans, United States , New York, United States , Phoenix, United States and 3 more locations